TabletsClinical Overview
Ofloxacin and Ornidazole is a broad-spectrum fixed-dose antimicrobial combination pairing a fluoroquinolone with a nitroimidazole. Ofloxacin halts bacterial DNA multiplication, while ornidazole damages microbial DNA through free nitro radicals, eradicating anaerobes and protozoa. Indicated for mixed bacterial and protozoal gastroenteritis, amoebic dysentery, pelvic inflammatory disease, dental infections, and post-surgical abdominal sepsis.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Swallow the tablet whole with a glass of water after food to minimize gastric irritation. Maintain copious hydration. Refrain from all alcohol intake during therapy and for 48 hours post-treatment. Complete the full prescribed course.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nausea, metallic taste, vomiting, dizziness, sleep disturbances, abdominal cramps. Rare/Severe: Tendonitis/tendon rupture, peripheral neuropathy, seizures, QT prolongation, and severe allergic reactions.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Avoid alcohol entirely to prevent severe adverse interactions. Fluoroquinolone safety warnings regarding tendon rupture, CNS toxicities, and peripheral neuropathy apply. Contraindicated in myasthenia gravis, epilepsy, and pregnancy.
Schedule H1 (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Ofloxacin Tablets 200mg
Ofloxacin is a synthetic fluoroquinolone bactericidal antibiotic. It acts by inhibiting bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and repair. Broad-spectrum activity encompasses Gram-negative bacteria, Chlamydia trachomatis, Mycoplasma, and Mycobacterium tuberculosis (second-line). Indicated for acute exacerbations of chronic bronchitis, community-acquired pneumonia, uncomplicated urethral and cervical gonorrhoea, pelvic inflammatory disease, and complicated UTIs.
Ofloxacin Tablets 400mg
Ofloxacin is a synthetic fluoroquinolone bactericidal antibiotic. It acts by inhibiting bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and repair. Broad-spectrum activity encompasses Gram-negative bacteria, Chlamydia trachomatis, Mycoplasma, and Mycobacterium tuberculosis (second-line). Indicated for acute exacerbations of chronic bronchitis, community-acquired pneumonia, uncomplicated urethral and cervical gonorrhoea, pelvic inflammatory disease, and complicated UTIs.
Ornidazole Tablets 500mg
Ornidazole is a synthetic nitroimidazole antiprotozoal and antibacterial agent. It is activated inside protozoa and anaerobic bacteria to form reactive reduced intermediates that interact with DNA, inhibiting nucleic acid synthesis. Indicated for acute amoebic dysentery, amoebic liver abscess, giardiasis, trichomoniasis, and anaerobic surgical and dental infections.
Cefixime 200mg + Ofloxacin 200mg Tablets
Cefixime and Ofloxacin is a fixed-dose combination antibiotic combining a 3rd-generation cephalosporin and a broad-spectrum fluoroquinolone. Cefixime inhibits cell wall synthesis, while ofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, halting DNA replication. This dual mechanism provides synergistic bactericidal coverage against resistant pathogens. Indicated for enteric fever (typhoid fever), severe respiratory tract infections, complicated urinary tract infections, and mixed bacterial pelvic infections.